{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-013513","form_type":"8-K/A","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.531135+00:00","generated_at":"2026-06-06T19:15:00.488335+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CalciMedica corrects private placement terms; raises up to ~$55M for clinical trials","bullets":["Corrected offering: 4,985,610 shares, 306,506 pre-funded warrants, 5,292,116 common warrants at $3.827/unit.","Upfront gross proceeds $20.4M; potential $33.1M from warrant exercise for total ~$54M (press release: ~$55M).","Preliminary cash Dec 31, 2023: $11.2M; net proceeds to fund Phase 2 trials of Auxora in AP and AKI.","New investors include Deerfield affiliate, Soleus Capital, Stonepine, Aisling; existing Sanderling and Bering participated.","Tranche A warrants ($5.36) expire Dec 31, 2024 or 30 days after AP topline; Tranche B ($7.15) expire Dec 31, 2026 or after AKI topline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-013513","json":"https://secwatch.observer/filing/0001193125-24-013513.json","markdown":"https://secwatch.observer/filing/0001193125-24-013513.md","text":"https://secwatch.observer/filing/0001193125-24-013513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/0001193125-24-013513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/d738337d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:15:00.488335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e53f0d737e644bd8d228f906066a899565ec0b7","claim":"CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $20.4 million (effective 2024-01-19).","evidence_excerpt":"On January 19, 2024, the Company and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/0001193125-24-013513-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$20.4 million"},{"label":"Effective","value":"2024-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}